Solgate

Executive Summary

Solgate is an Austrian biotechnology company headquartered in Vienna, founded in 2019. The company is dedicated to discovering and developing transformative medicines targeting membrane transporter proteins, specifically solute carriers (SLCs), a class of targets historically considered challenging due to their complex biology and limited druggability. Solgate’s core asset is a proprietary cell-based technology platform designed to accelerate drug discovery against SLC transporters. This platform enables high-throughput screening and functional characterization, aiming to unlock the therapeutic potential of SLCs for severe diseases. As a private, early-stage entity, Solgate has not disclosed specific pipeline programs or financing details, but its focus on an emerging target class positions it within a niche area of high interest in the pharmaceutical industry. The company operates in Vienna, a growing biotech hub, and leverages local academic and research infrastructure. With the increasing recognition of SLC transporters as viable drug targets, Solgate’s platform approach could enable multiple drug discovery programs, potentially attracting partnerships or investment to advance its lead candidates toward preclinical and clinical development.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round70% success
• Q4 2026Lead Program Nomination or IND-Enabling Studies Initiation60% success
• Q2 2027Pharmaceutical Partnership or Collaboration Agreement50% success